A population-based survey of prostate-specific antigen testing among California men at higher risk for prostate carcinoma

Cancer

Volumn 106, Issue 4, 2006, Pages 765-774

  Spencer, Benjamin A ^a,b,c   Babey, Susan H ^c   Etzioni, David A ^a,c   Ponce, Ninez A ^c,d   Brown, E Richard ^c,d   Yu, Hongjian ^c   Chawla, Neetu ^c   Litwin, Mark S ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

African American; High risk; Prostate carcinoma; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGE; AGED; CANCER SCREENING; CANCER SURVIVAL; EARLY DIAGNOSIS; FAMILY HISTORY; HEALTH SERVICE; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RACE; REVIEW; SELF REPORT; UNITED STATES;

AFRICAN AMERICANS; AGE FACTORS; AGED; CALIFORNIA; GENETIC PREDISPOSITION TO DISEASE; HEALTH BEHAVIOR; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PEDIGREE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SOCIAL CLASS;

EID: 32544458970     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21673     Document Type: Review

References (44)

1. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-552.
2. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet, 1994;343:251-254.
3. Merrill RM, Potosky AL, Feuer EJ. Changing trends in U.S. prostate cancer incidence rates. J Natl Cancer Inst. 1996;88: 1683-1685.
4. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017-1024.
5. Vijayakumar S, Vaida F, Weichselbaum R, Hellman S. Race and the Will Rogers phenomenon in prostate cancer. Cancer J Sci Am. 1998;4:27-34.
6. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
7. Merrill RM, Stephenson RA. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening. J Urol. 2000;163:503-510.
8. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA. 2003;289:1414-1420.
9. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003;97:1528-1540.
10. Lu-Yao G, Stukel TA, Yao SL. Prostate-specific antigen screening in elderly men. J Natl Cancer Inst. 2003;95:1792-1797.
11. Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 2002;52:8-22.
12. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:917-929.
13. American College of Physicians. Screening for prostate cancer. Ann Intern Med. 1997;126:480-484.
14. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. Br J Urol Int. 2003;91:789-794.
15. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer. 2003;107:797-803.
16. Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am. 2002;29:173-181.
17. Merrill RM, Brawley OW. Prostate cancer incidence and mortality rates among white and black men. Epidemiology. 1997;8:126-131.
18. Moul JW, Sesterhenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995;274:1277-1281.
19. Zagars GK, Pollack A, Pettaway CA. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys. 1998;42:517-523.
20. Powell IJ, Banerjee M, Sakr W, et al. Should African-American men be tested for prostate carcinoma at an earlier age than white men? Cancer. 1999;85:472-477.
21. Iselin CE, Box JW, Vollmer RT, Layfield LJ, Robertson JE, Paulson DF. Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. Cancer. 1998;83:2353-2360.
22. Sakr WA, Grignon DJ, Haas GP. Pathology of premalignant lesions and carcinoma of the prostate in African-American men. Semin Urol Oncol. 1998;16:214-220.
23. Schapira MM, McAuliffe TL, Nattinger AB. Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease. Med Care. 1995;33:1079-1088.
24. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287:2106-2113.
25. Myers RE, Chodak GW, Wolf TA, et al. Adherence by African-American men to prostate cancer education and early detection. Cancer. 1999;86:88-104.
26. de Koning HJ, Auvinen A, Berenguer Sanchez A, et al. Largescale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer. 2002;97:237-244.
27. Hiatt RA, Klabunde C, Breen N, Swan J, Ballard-Barbash R. Cancer screening practices from National Health Interview Surveys: past, present, and future. J Natl Cancer Inst. 2002;94:1837-1846.
28. Centers for Disease Control and Prevention. 2002 Behavioral risk factor surveillance system summary data quality report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2003.
29. California Health Interview Survey. CHIS 2001 methodology series: report 4-response rates. Los Angeles: UCLA Center for Health Policy Research, 2002.
30. California Health Interview Survey. CHIS 2001 methodology series: report 1-sample design. Los Angeles: UCLA Center for Health Policy Research, 2002.
31. California Health Interview Survey. CHIS 2001 methodology series: report 2-data collection methods. Los Angeles: UCLA Center for Health Policy Research, 2002.
32. California Health Interview Survey. CHIS 2001 methodology series: report 3-data processing procedures. Los Angeles: UCLA Center for Health Policy Research, 2002.
33. California Health Interview Survey. CHIS 2001 methodology series: report 5-weighting and variance estimation. Los Angeles: UCLA Center for Health Policy Research, 2002.
34. McNaughton Collins M, Stafford RS, Barry MJ. Age-specific patterns of prostate-specific antigen testing among primary care physician visits. J Fam Pract. 2000;49:169-172.
35. Steele CB, Miller DS, Maylahn C, Uhler RJ, Baker CT. Knowledge, attitudes, and screening practices among older men regarding prostate cancer. Am J Public Health. 2000;90:1595-1600.
36. Taylor KL, DiPlacido J, Redd WH, Faccenda K, Greer L, Perlmutter A. Demographics, family histories, and psychological characteristics of prostate carcinoma screening participants. Cancer. 1999;85:1305-1312.
37. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690-1691.
38. Etzioni R, Berry KM, Legler JM, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of Medicare claims from 1991-1998. Urology. 2002;59:251-255.
39. Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA. 2000;284:1399-1405.
40. Cormier L, Kwan L, Reid K, Litwin MS. Knowledge and beliefs among brothers and sons of men with prostate cancer. Urology. 2002;59:895-900.
41. Cormier L, Reid K, Kwan L, Litwin MS. Screening behavior in brothers and sons of men with prostate cancer. J Urol. 2003;169:1715-1719.
42. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781-789.
43. Sox HC, Mulrow C. An editorial update: should benefits of radical prostatectomy affect the decision to screen for early prostate cancer? Ann Intern Med. 2005;143:232-233.
44. Jordan TR, Price JH, King KA, Masyk T, Bedell AW. The validity of male patients' self-reports regarding prostate cancer screening. Prev Med. 1999;28:297-303.